|
Cours en clôture
24/09/2026
|
Varia. 5j.
|
Varia. 1 janv.
|
|
30,95 TWD
|
-1,75%
|
 |
+0,16%
|
-21,89%
|
|
11/08 |
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
| | |
21/07 |
GenEditBio Limited announced that it has received TWD 550 million in funding from Center Laboratories, Inc.
| | |
13/05 |
Center Laboratories says Jan-Mar net profit at T$1.97 bln
| | |
13/05 |
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
| | |
14/04 |
Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026
| | |
31/03 |
WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders.
| | |
03/03 |
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
| | |
14/01 |
WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion.
| | |
11/11 |
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
| | |
13/08/25 |
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
| | |
09/06/25 |
Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025.
| | |
09/06/25 |
Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million.
| | |
11/05/25 |
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
| | |
08/05/25 |
Medeon Biodesign, Inc. cancelled the transaction announced on February 29, 2024
| | |
09/04/25 |
Center Laboratories, Inc. announces an Equity Buyback for 20,000,000 shares, representing 2.76% for TWD 9,141.18 million.
| | |
09/04/25 |
Center Laboratories, Inc. authorizes a Buyback Plan.
| | |
24/03/25 |
Guangzhou Hybot Technology Co., Ltd. announced that it has received CNY 450 million in funding from CS Capital Co., Ltd., Beijing Taiji Huaqing Peicheng Software Technology Co., Ltd., Hydrogenics Corporation, Guangzhou Shuimu Qingyun Equity Investment Partnership Enterprise (Limited Partnership), Beijing Shunyuan Changxin Consulting Management Partnership Enterprise (Limited Partnership, Hainan Yide Investment Partnership Enterprise (Limited Partnership), Center Laboratories, Inc.
| | |
14/03/25 |
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
| | |
11/03/25 |
Center Laboratories, Inc. Proposes Dividend for Year Ended December 31, 2024
| | |
11/03/25 |
Center Laboratories, Inc. announced a financing transaction
| | |
27/02/25 |
Mycenax Biotech Inc. cancelled the transaction announced on March 13, 2024
| | |
14/11/24 |
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
| | |
23/10/24 |
Shanghai Bao Pharmaceuticals Co., Ltd. announced that it has received CNY 425.748904 million in funding from Shanghai STCV Group, Shanghai Industrial Investment Co. Ltd., Investment Arm, Shanghai Shangshi Capital Management Co., Ltd., Shanghai Baoshan State Owned Capital Investment Management Co., Ltd., Center Laboratories, Inc.
| | |
25/09/24 |
Lumosa Therapeutics Co., Ltd. announced that it has received TWD 236.083275 million in funding from Center Laboratories, Inc.
| | |
13/08/24 |
Center Laboratories, Inc. Appoints Kuo-Lung Yen as Member of Remuneration Committee
| |
Aucun résultat pour cette recherche Sélectionnez votre édition Toutes les informations financières adaptées au niveau national | 
